B+
Bull case
25%
Probability
Target price
$2.00
+51.5% vs current
PULM
PulmatrixDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$1.20
-9.1% vs current
B-
Bear case
30%
Probability
Target price
$0.40
-69.7% vs current
AI sentiment snapshot
Latest data as of 2026-05-16
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+36.5
Score
AI commentary
The post-earnings filing set materially confirmed the thesis change, but the tone remains monitoring-oriented rather than bullish. The May 15 8-K and Q1 release mainly reiterated the Eos merger, the $1.0 million preferred financing already tied to that deal, and a limited cash bridge rather than showing renewed internal program momentum [#8-K-2026-05-15]. No reliable analyst revision or target-change set was available in the evidence packet after the print, and with only the May 15 anchor price of $1.25 in the packet, the immediate market-reaction read-through remains limited. Net result: evidence is usable but tentative because the stock is still primarily a merger-and-runway situation.
RankAlpha Sentiment Codex - 2026-05-16
Open post-earnings memoEvidence flagged
Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.
Impact
tentative
Confidence
-
AI events
2026-09-30eventEos merger closing remains the key near-term value gateHigh impact
Pulmatrix said the proposed merger with Eos SENOLYTIX is anticipated to close in the third quarter of 2026, subject to customary closing conditions. The 10-Q says future operations are highly dependent on the merger's success; if it fails, the company may need to pursue other strategic alternatives or liquidation. The same filing says Pulmatrix stockholders are expected to own about 6% of the combined company on a fully diluted basis, while concurrent financings total $19 million in aggregate gross proceeds including $1.0 million invested in Pulmatrix [#10-Q-2026-05-15] [#8-K-2026-05-15].
2026-12-31catalystAsset monetization remains the main standalone upside outside the mergerHigh impact
Management said all U.S. clinical development is currently on hold while Pulmatrix works to license or monetize its clinical assets. PUR3100 remains Phase 2-ready with prior FDA IND acceptance, while PUR1800 and the iSPERSE platform are also being positioned for partnering or monetization; any transaction would matter disproportionately at the current micro-cap equity value, but timing and counterparties remain uncertain [#10-Q-2026-05-15] [#8-K-2026-05-15].
2026-12-31catalystCipla-led PUR1900 Phase 3 start in India is a real but lower-visibility external optionHigh impact
Pulmatrix said partner Cipla completed a Phase 2 study in India, published positive results, and received approval from India's regulator to proceed to a Phase 3 trial that Cipla expects to commence in 2026. Pulmatrix would receive 2% royalties on future ex-U.S. net sales, so a trial start would help validate residual platform value, but it is partner-controlled and likely secondary to the merger thesis [#8-K-2026-05-15].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-16 • Updated nightlySource: Internal modelMethodology